Table 1 Clinical trials of targeted mitotic inhibitors

CDK2, CDK5, CDK1, CDK9

Venetoclax and dinaciclib (MK7965)

AML, relapsed/refractory

I

Recruiting

NCT03484520

CDK2, CDK5, CDK1, CDK9

Dinaciclib or gemtuzumab ozogamicin

AML/ALL, relapsed/refractory

II

Terminated

NCT00798213 [71]

PLK1 and other kinases

Oral rigosertib

AML, ALL, MDS, CLL, CML, relapsed/refractory

I

Completed

NCT00854646 [72]

PLK1 and other kinases

Rigosertib

AML, ALL, CML, relapsed/refractory, transformed MPN

I/II

Completed

NCT01167166 [73]

PLK1 and other kinases

Oral rigosertib

AML, MDS, relapsed/refractory or ineligible for standard chemotherapy

I/II

Completed

NCT00854945 [74]

PLK1 and other kinases

Oral rigosertib in combination with azacitidine

MDS, CMML, RAEB-t/non-proliferative AML

I/II

Active, not recruiting

NCT01926587 [75]

PLK1

Volasertib

AML, relapsed/refractory or ineligible for standard induction therapy

I

Completed

NCT01662505 [76]

PLK1

Volasertib

Pediatric leukemia, relapsed/refractory, advanced solid tumors, no available effective treatments

I

Completed

NCT01971476 [77]

PLK1

BI 6727 (volasertib) as monotherapy or in combination with cytarabine

AML, relapsed/refractory or ineligible for intensive induction therapy

II

Active, not recruiting

NCT00804856 [78, 79]

PLK1

Volasertib in combination with low-dose Cytarabine

Newly diagnosed AML, aged ≥ 65 years, ineligible for intensive induction therapy

III

Active, not recruiting

NCT01721876 [80]

PLK1

Volasertib in combination with decitabine

AML, aged ≥ 65 years, newly diagnosed and ineligible for standard intensive therapy or relapsed/refractory

I

Terminated

NCT02003573

PLK1

Intensive chemotherapy with or without volasertib

AML, newly-diagnosed, high-risk MDS

II

Terminated

NCT02198482

PLK1

Onvansertib in combination with either low-dose cytarabine or decitabine

AML, relapsed/refractory or ineligible for intensive induction therapy

Ib/II

Recruiting

NCT03303339 [81]

PLK4 (and Aurora B)

CFI-400945

AML, MDS, relapsed/refractory

I

Recruiting

NCT03187288

Aurora A

MLN8237

Recurrent childhood AML, ALL, solid tumors

II

Completed

NCT01154816 [82]

Aurora A

MLN8237

AMKL, MF

I

Active, not recruiting

NCT02530619 [83]

Aurora A

MLN8237

AML, relapsed/refractory or ineligible for intensive induction therapy, high-grade MDS

II

Completed

NCT00830518 [84]

Aurora A

MLN8237 in combination with 7+3 induction chemotherapy

Newly diagnosed AML

I

Completed

NCT01779843 [85]

Aurora A

MLN8237 with induction chemotherapy

High-risk AML, newly diagnosed

II

Active, not recruiting

NCT02560025 [86]

Aurora A

MLN8237 in combination with vorinostat

B/T ALL, CLL, lymphoma, relapsed/refractory

I

Completed

NCT01567709 [82]

Aurora B

AZD1152

AML, relapsed/refractory or ineligible for other treatments

I

Completed

NCT00530699 [87]

Aurora B

AZD1152

AML, relapsed/refractory or ineligible for other treatments

I/II

Completed

NCT00497991 [88]

Aurora B

AZD1152 in combination with low-dose cytosine arabinoside (LDAC)

AML, newly diagnosed, ineligible for other treatments, aged ≥ 60

I

Completed

NCT00926731 [89]

Aurora B

AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC)

AML, newly diagnosed, aged ≥ 60

II/III

Completed

NCT00952588 [90]

Aurora B

AZD2811 nanoparticles alone and in combination with azacitidine

AML, high-risk MDS

I/II

Recruiting

NCT03217838 [91]

Aurora A/B and other kinases

AT9283

Acute leukemia, childhood, adult, relapsed/refractory,

I

Completed

NCT01431664 [92]

Aurora A/B and other kinases

AT9283

AML, ALL, relapsed/refractory or ineligible for standard therapy, high-risk MDS, refractory CML

I/II

Terminated

NCT00522990 [93]

Aurora A/B

Orally administered AMG 900

AML, refractory or ineligible for standard therapies

I

Completed

NCT01380756 [94]

Aurora A/B and other kinases

MK-0457

CML, Ph+ ALL

I

Terminated

NCT00500006 [95]

Aurora A/B and other kinases

MK-0457

T315I mutant CML, Ph + All

II

Terminated

NCT00405054 [96]

Aurora A/B and other kinases

MK-0457

AML, relapsed/refractory, high-risk MDS, B-ALL, myeloproliferative diseases, CML in blast crisis

I/II

Completed

NCT00111683 [97]

Aurora A/B and other kinases

AS703569/MSC1992371A

AML, ALL, CLL, NHL, relapsed/refractory, or ineligible for standard therapy; high-risk MDS, CML, resistant or intolerant to standard treatment; myeloproliferative disorders with no effective treatment options.

I

Terminated

NCT01080664 [98]

Aurora A and other kinases

ENMD-2076

AML, ALL, CLL, relapsed/refractory; high-risk MDS, CML

I

Completed

NCT00904787 [99]